Evidence map›Paper›PMID 30848433›Full record

ReviewReviews in endocrine & metabolic disorders2019

Therapeutic hypernatremia management during continuous renal replacement therapy with elevated intracranial pressures and respiratory failure.

Tibor Fülöp, Lajos Zsom, Rafael D Rodríguez, Jorge O Chabrier-Rosello, Mehrdad Hamrahian, Christian A Koch

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Guideline
  2. Renal failure · 2024
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Tibor FülöpDepartment of Medicine - Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA. tiborfulop.nephro@gmail.com.
Lajos ZsomFresenius Medical Care Hungary Kft, Cegléd, Hungary.
Rafael D RodríguezDepartment of Medicine - Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA.
Jorge O Chabrier-RoselloDepartment of Medicine - Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA.
Mehrdad HamrahianDepartment of Medicine - Division of Nephrology, Thomas Jefferson University, Philadelphia, PA, USA.
Christian A KochMedicover GmbH, Berlin, Germany. Christian.koch65@gmail.com.
Medical University of South Carolina · USMedicover · DEThomas Jefferson University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebral edema and elevated intracranial pressure (ICP) are common complications of acute brain injury. Hypertonic solutions are routinely used in acute brain injury as effective osmotic agents to lower ICP by increasing the extracellular fluid tonicity. Acute kidney injury in a patient with traumatic brain injury and elevated ICP requiring renal replacement therapy represents a significant therapeutic challenge due to an increased risk of cerebral edema associated with intermittent conventional hemodialysis. Therefore, continuous renal replacement therapy (CRRT) has emerged as the preferred modality of therapy in this patient population. We present our current treatment approach, with demonstrative case vignette illustrations, utilizing hypertonic saline protocols (3% sodium-chloride or, with coexisting severe combined metabolic and respiratory acidosis, with 4.2% sodium-bicarbonate) in conjunction with the CRRT platform, to induce controlled hypernatremia of approximately 155 mEq/L in hemodynamically unstable patients with acute kidney injury and elevated ICP due to acute brain injury. Rationale, mechanism of activation, benefits and potential pitfalls of the therapy are reviewed. The impact of hypertonic citrate solution during regional citrate anticoagulation is specifically discussed. Maintaining plasma hypertonicity in the setting of increased ICP and acute kidney injury could prevent the worsening of ICP during renal replacement therapy by minimizing the osmotic gradient across the blood-brain barrier and maximizing cardiovascular stability.

Indexed as

Brain InjuriesContinuous Renal Replacement TherapyHumansHypernatremiaIntracranial HypertensionRespiratory InsufficiencySaline Solution, HypertonicSaline Solution, HypertonicAcute kidney injuryBlood-brain barrierBrain injuryContinuous renal replacement therapyHypernatremiaIntracranial pressureNeurosurgeryRegional citrate anticoagulationRhabdomyolysisSerum osmolalityVolume overload

Identifiers

PMID30848433
OpenAlexW2921713631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.